Samples and panel design
cancer, tumor, cancers
TUMOR, CANCERS, CANCER, DNA DAMAGE, SOLID TUMORS
Biomarker analysis was conducted using a capture-based sequencing panel targeting 561 genes. DNA was extracted form formalin fixed paraffin embedded tumor sample. The capture-based sequencing panel used in this study was designed and provided by Precision Scientific (Beijing) Co., Ltd. This panel comprises 561 genes frequently mutated in solid tumors and closely associated with precision therapy in cancers, including 201 cancer driver genes, 51 cancer predisposition genes, 44 genes appearing in key DNA damage repair pathways, 174 genes possessing actionable mutation spots of targeted therapy and 28 immuno-oncology genes. Probes of this panel cover exonic regions of all genes and hotspots in intronic or promoter regions of part of them, enabling the comprehensive analysis for mutational profiling of cancers.